{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T22:44:56Z","timestamp":1768517096612,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009448","name":"University of Campania Luigi Vanvitelli","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.esmorw.2024.100108","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T15:47:34Z","timestamp":1736783254000},"page":"100108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center\u2019s real-world approach"],"prefix":"10.1016","volume":"7","author":[{"given":"E.","family":"Cioli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Suarato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Forte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.","family":"Laudato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Morgillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Orditura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Della Corte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Troiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"De Falco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmorw.2024.100108_bib1","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/bph.16337","article-title":"Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: a year in review","volume":"181","author":"Apapetropoulos","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"11","key":"10.1016\/j.esmorw.2024.100108_bib2","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.esmorw.2024.100108_bib3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.esmorw.2024.100108_bib4","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9742","key":"10.1016\/j.esmorw.2024.100108_bib5","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.esmorw.2024.100108_bib7","first-page":"473","article-title":"Advances in drug development: off-label drug utilization in oncology","volume":"9","author":"de Souza","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"10.1016\/j.esmorw.2024.100108_bib8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00228-011-1173-6","article-title":"Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience","volume":"68","author":"Lerose","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.esmorw.2024.100108_bib9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/jcpt.12507","article-title":"Off-label drug use in oncology: a systematic review of literature","volume":"42","author":"Saiyed","year":"2017","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.esmorw.2024.100108_bib10","article-title":"Real-world analysis of off-label use of molecularly targeted therapy in a large Academic Medical Center Cohort","volume":"6","author":"Upadhyay","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100108_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1167","article-title":"Real-world treatment outcomes of immune checkpoint inhibitors used off-label in oncology: a comprehensive cancer institution experience","volume":"12","author":"Fontanals","year":"2024","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"10.1016\/j.esmorw.2024.100108_bib13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmorw.2024.100108_bib14","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmorw.2024.100108_bib15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmorw.2024.100108_bib16","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/S1470-2045(08)70280-8","article-title":"Off-label use of anticancer drugs","volume":"9","author":"Lev\u00eaque","year":"2008","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmorw.2024.100108_bib17","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3390\/cancers15061727","article-title":"Role of the molecular tumor board for the personalized treatment of patients with metastatic breast cancer: a focus on the state of the art in Italy","volume":"15","author":"Irelli","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.esmorw.2024.100108_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s43018-022-00332-x","article-title":"The molecular tumor board portal supports clinical decisions and automated reporting for precision oncology","volume":"3","author":"Tamborero","year":"2022","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.esmorw.2024.100108_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000675","article-title":"Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania \u2018Luigi Vanvitelli\u2019","volume":"5","author":"De Falco","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmorw.2024.100108_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221096878","article-title":"Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience","volume":"14","author":"Caputo","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100108_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.37349\/etat.2023.00125","article-title":"Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer","volume":"4","author":"Caputo","year":"2023","journal-title":"Explor Target Antitumor Ther"},{"issue":"1","key":"10.1016\/j.esmorw.2024.100108_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-022-00312-5","article-title":"MatchMiner: an open-source platform for cancer precision medicine","volume":"6","author":"Klein","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmorw.2024.100108_bib23","first-page":"3087","article-title":"Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: first analysis of the ROME trial","volume":"40","author":"Andrea","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820124000869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820124000869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T22:47:53Z","timestamp":1747349273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820124000869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":21,"alternative-id":["S2949820124000869"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2024.100108","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center\u2019s real-world approach","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2024.100108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100108"}}